Simplify Asset Management Inc. Takes Position in Palisade Bio, Inc. $PALI

Simplify Asset Management Inc. acquired a new stake in Palisade Bio, Inc. (NASDAQ:PALI) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 350,000 shares of the company’s stock, valued at approximately $612,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Creek Drive Management Group LLC purchased a new stake in Palisade Bio during the fourth quarter worth about $723,000. Caitong International Asset Management Co. Ltd purchased a new position in Palisade Bio in the fourth quarter valued at about $81,000. Seven Fleet Capital Management LP acquired a new stake in shares of Palisade Bio during the 4th quarter valued at approximately $770,000. Virtu Financial LLC acquired a new stake in shares of Palisade Bio during the 4th quarter valued at approximately $28,000. Finally, XTX Topco Ltd boosted its stake in shares of Palisade Bio by 53.8% during the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock worth $51,000 after acquiring an additional 7,584 shares in the last quarter. Institutional investors and hedge funds own 11.79% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on PALI. Wolfe Research assumed coverage on Palisade Bio in a report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 price target on the stock. Weiss Ratings upgraded Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Wall Street Zen downgraded Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday, June 27th. LADENBURG THALM/SH SH raised Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Finally, Oppenheimer set a $7.00 price target on Palisade Bio in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $8.83.

Palisade Bio Stock Performance

Palisade Bio stock opened at $2.10 on Friday. The stock has a fifty day moving average of $1.92 and a two-hundred day moving average of $1.91. The company has a market capitalization of $364.52 million, a price-to-earnings ratio of -2.08 and a beta of 1.50. Palisade Bio, Inc. has a fifty-two week low of $0.53 and a fifty-two week high of $2.85.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). On average, analysts forecast that Palisade Bio, Inc. will post -0.25 EPS for the current fiscal year.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.